Background
UniProt entry O95436 emerges as a putative target candidate in glioblastoma multiforme (GBM), a highly aggressive and lethal brain tumor with limited therapeutic options. This protein has been detected in multiple gene expression profiling studies related to GBM, suggesting a potential role in tumor biology. However, O95436 has not yet been linked to any registered clinical programs or advanced drug development efforts in this indication. Its biological functions and involvement in GBM pathophysiology remain to be elucidated, positioning it as a hypothesis-generating candidate warranting further experimental validation.
Data-mining rationale
The identification of O95436 as a candidate target originated from a cross-referencing approach that integrated UniProt’s reviewed human protein entries annotated for glioblastoma multiforme with a comprehensive reanalysis of 724 microarray datasets housed in the NCBI Gene Expression Omnibus (GEO). Several GEO datasets (GDS:200317497, GDS:200273558, GDS:200320501, GDS:200318047, GDS:200318046) include expression profiles from GBM samples in which O95436 is represented. This integrative data-mining strategy highlights O95436 as a recurrently expressed gene in GBM contexts, meriting deeper investigation into its expression patterns and potential functional roles.
Why prior analyses may have missed this
Many of the GEO datasets containing O95436 expression data predate the widespread adoption of modern empirical-Bayes statistical methods such as limma, which provide robust differential expression analysis with appropriate multiple-testing corrections (e.g., Benjamini-Hochberg false discovery rate control). Earlier analyses may have lacked sufficient statistical rigor or power to detect O95436 as a significant differentially expressed gene in GBM, leading to its underappreciation in the literature and target discovery pipelines. Additionally, the absence of registered clinical programs targeting O95436 suggests it has not been prioritized for translational research, further contributing to its current status as an overlooked candidate.
Reasoning for further validation
To clarify the potential relevance of O95436 in glioblastoma multiforme and assess its suitability as a therapeutic target, the following experimental steps are recommended:
- Re-analysis of GEO datasets: Apply limma with Benjamini-Hochberg false discovery rate correction to the matched GBM microarray datasets to robustly determine differential expression of O95436 and related genes.
- Independent validation: Quantify O95436 expression by quantitative PCR in an independent cohort of GBM patient samples to confirm reproducibility of expression patterns.
- Tissue specificity assessment: Evaluate O95436 expression across normal and tumor tissues using resources such as GTEx and the Human Protein Atlas to understand its distribution and potential off-target risks.
- Pathway and interaction analysis: Utilize protein interaction databases like STRING and OmniPath to place O95436 within relevant molecular pathways and identify potential functional partners in GBM biology.
- Druggability evaluation: If expression and pathway analyses support a role in GBM, assess the druggability of O95436 through databases such as DGIdb and ChEMBL to explore existing compounds or chemical scaffolds that may modulate its activity.
These steps will provide critical data to determine whether O95436 represents a viable and novel target for therapeutic intervention in glioblastoma multiforme.